At Best Startup UK we track over 130,000 UK startups and over 500,000 people who hold key positions in these companies. We use this directory of startups to highlight top employees, founders and board members we think deserve more appreciation than they are currently getting.
This list showcases the top United Kingdom based Founder operating in the Health Diagnostics space. If you think a Founder is missing from this list, feel free to contact our editor on editor@beststartup.co.uk.
The individuals on this list have been included because of exceptional performance in one of the following categories:
- Innovation – Operating as a key part in an extremely innovative business or startup.
- Growth – Operating as a key figure in the growth and upscale of a market leading business or startup.
- Management – Showing exceptional management skills.
- Societal impact – Putting their business on the map for their positive societal or environmental impact.
Our Data – We source our data from OSINT (open source intelligence) and public directories such as Companies House UK, Crunchbase, SemRush and many more. The data from these sources should be treated with a degree of caution and verified yourself.
Siro Perez
Co-Founder & CEO of Molecular Warehouse
Follow Siro Perez:
About IP Group, Kira Biotech, Molecular Warehouse: Molecular Warehouse is creating a world where most diseases are prevented, by giving people the power of molecular diagnostics and mHealth.
_______
Nikita Alexandrov
Co-Founder of Molecular Warehouse
Nikita brings advanced expertise in instrumentation and high throughput research techniques. Prior to MW, he founded Permanetix Corporation, developing technology in the field of Fusion energy. Previously, he was the first employee in the aerospace materials testing start-up XEEL Corp, where he developed tools and techniques for high energy testing of space flight hardware for NASA. Nikita graduated from Auburn University (USA) in 2012, with a degree in chemistry, focusing on analytical chemistry, where he received his own lab to conduct chemical plasma reactor research and development. Nikita has an MBA from the University of Alabama (USA).
Follow Nikita Alexandrov:
About Molecular Warehouse: Molecular Warehouse is creating a world where most diseases are prevented, by giving people the power of molecular diagnostics and mHealth.
Mayank Banerjee
Co-Founder and CEO of Even
Mayank Banerjee joined Even Healthcare as Co-Founder in 2020.
Follow Mayank Banerjee:
About Even: Even is a health-tech company and healthcare provider that partners directly with the top hospitals in the country.
Connor Campbell
Founder and CEO of Osler Diagnostics
Follow Connor Campbell:
About Osler Diagnostics: Lab-quality diagnostics for anyone, anywhere, at any time.
Paulo R. Bueno
Co-Founder of Osler Diagnostics
Paulo R. Bueno is the coordinator of the Nanobionics research group (www.nanobionics.pro.br) at São Paulo State University, UNESP. He published over 180 papers related to fundaments and applications of electric and electrochemistry time-dependent (including gravimetric and optical impedance) spectroscopic methods (h index 42, > 6500 citations with an average citation of higher than 25 per article, Google Scholar). His main scientific interest is focused on the fundaments and technological applications associated with electron charge transfer, transport and storage occurring at molecular and nanoscale structures. Under his guidance Nanobionics group develops synthetic structures and surfaces that mimic molecular and biological structures aiming applications in highly-relevant diagnostic devices. The Nanobionics group developed a totally new label-free diagnostic assay based on an electroanalytical spectroscopic methodology supported on the use of the electrochemistry capacitance, i.e. a capacitance proportional to the electrochemical density of states that intrinsically exists in mesoscopic structures comprised of redox-active molecules when attached over an electrode. These impedance-derived assays are able to detect target protein at femtomolar levels allowing the early detection of clinically relevant targets that are better than those currently commercial. They are potentially cheap and can be multiplexed. Other relevant aspects of his groups’ activities are the synthesis of self-assembled redox-tagged peptides and its applications in redox capacitive biosensors. The advantages of constructing a peptide-based receptive surface containing electrochemical tags are that peptides can be easily manipulated and optimized for applications containing complex biological environments. This tailoring ability avoids fouling and concomitantly can substitute antibodies by peptide or DNA aptamers as receptors with equivalent or superior affinity as well as specificity. Since 2008 Professor Bueno is engaged with tech transfer initiatives involving public-private start-up tech transfer projects with Scientific and Technological Parks in Sao Paulo. Because of such initiatives, Professor Bueno was invited to a plenary conference in the USA – Washington in 2009 by the US National Council of Entrepreneurial Tech Transfer in which Brazilian Tech Transfer context was introduced and discussed with the US and European Tech Transfer related agents and agencies. He is also engaged with UNESP internationalization program. Finally, he acted as academic and researcher visitor several times in European universities such as Universities of Valence and Jaume I (Spain), University of Paris (France) and University of Oxford. His collaborative work has been the subject of two significant awards from The Royal Society in the UK (a Brian Mercer Award in 2013 and a Newton Fellowship in 2015). His is currently administrating a Fellowship of Royal Society (Research Fellows Director, https://royalsociety.org/people/paulo-roberto-bueno-12682/). He is Fellows of Royal Society of Chemistry (FRSC) in the UK and member of American Chemical Society (ACS) in the USA. Also, he is a member of The Electrochemical Society (ECS) and International Society of Electrochemistry (ISE). Professor Bueno is the co-founder of Osler Diagnostics (http://oslerdiagnostics.com/), a start-up company from the University of Oxford.
Follow Paulo R. Bueno:
About Osler Diagnostics: Lab-quality diagnostics for anyone, anywhere, at any time.
Rafael López Schietekat
Founder & Managing Director of Diagnostikare
Follow Rafael López Schietekat:
About Diagnostikare: The first data-driven patient-centric virtual primary care platform in Mexico.
Matteo Berlucchi
CEO & Co-Founder of Healthily by Your.MD
Matteo’s digital career spans 20 years, during which he has conceived, built and launched several successful companies and services both online and on mobile. Most recently, Matteo was Chief Digital Officer at Northern & Shell, the largest independent media company in the UK,where he grew traffic and revenues 4-fold in just 12 months. Matteo was also the founder and CEO of aNobii, the ebook platform funded by Penguin Random House, HarperCollins which was acquired by Sainsbury’s in 2012. Matteo founded Livestation, the leading service for live TV news online and the first company in the world to stream live TV on iPhones. Livestation is also the winner of the Guardian Digital Innovation Award 2008. Prior to this, Matteo was CEO and co-founder of Skinkers, a software company, which defined the market for desktop widgets and the winner of several international innovation awards in the digital space. Matteo started his career by launching the first online property system in Europe in 1995.
Follow Matteo Berlucchi:
About Healthily by Your.MD, Vini Italiani: Healthily is the world’s first medically approved self-care app designed around you.
Andrew Shepherd
Co-Founder & Managing Director of Omega Diagnostics
Andrew Shepherd is the Founder and Managing Director of Omega Diagnostics Limited. He is responsible for corporate strategy, general management, sales and marketing and technical direction. He has been involved in the medical diagnostics industry for the last 35 years. He started his career in 1974 by holding technical positions at G.D. Searle Limited and then attended university, graduating with a Bachelor of Science in Biology. He then moved into a sales and marketing position at Cambridge Life Sciences plc in 1981, before establishing his first diagnostics company, Cambridge Biomedical Limited in 1982. In 1986 he moved to Scotland to join Bioscot Limited and shortly afterwards, established Omega. Shepherd used his technical experience and knowledge of exporting to oversee the growth of the export of Omega products to exceed £2 million per annum. Omega now exports to over 100 countries around the world, and he travels regularly to many of the countries in which Omega customers are based. Shepherd is an active member of a number of relevant trade associations and was a member of the Scottish Exports Forum, a body which reported to the Scottish Parliament to oversee and guide the export activity of Scottish Development International. Mr Shepherd was also a member of the Bill & Melinda Gates Foundation’s (BMGF) Global Health Diagnostics Forum, which provides direct guidance to BMGF in advising on future investments in worldwide diagnostics programmes for developing countries.
Follow Andrew Shepherd:
About Global DX Ltd, Omega Diagnostics: Omega Diagnostics provides IVD products for use in hospitals, blood banks, clinics, and laboratories.
Aris Papageorghiou
Co-Founder & CMO of Intelligent Ultrasound
Aris Papageorghiou is the Professor of Fetal Medicine at University of Oxford.
Follow Aris Papageorghiou:
About Intelligent Ultrasound, Royal College of Obstetricians and Gynaecologists, St Georges University Hospitals NHS Foundation Trust, Ultrasound Diagnostic Services, University of Oxford: Intelligent Ultrasound develops software that improves the quality, reliability, and diagnostic power of medical ultrasound.
Andrew Barker
Co-Founder & Director of Intelligent Ultrasound
Andrew Barker is the Chairman at Oxford Brain Diagnostics .
Follow Andrew Barker:
About Anchard Associates, Brainomix, Intelligent Ultrasound, Oxford Brain Diagnostics: Intelligent Ultrasound develops software that improves the quality, reliability, and diagnostic power of medical ultrasound.
Aron Rachamim
Founder & CEO of Senzo
Aron Rachamim is committed to changing the world by putting healthcare information into everyone’s hands. A serial entrepreneur, scientist, and experienced leader, Aron aims to apply pioneering technologies to improve people’s quality of life. His expertise and passion for the science of microfluidics builds on his background in life sciences, physics, and engineering. His company Orphidia intends to transform the world of medical diagnostics. Aron launched Orphidia in 2013 to provide affordable, point-of-care diagnostics that allow everyone to know their health. Orphidia has advanced the state-of-the-art with microfluidic-based medical diagnostics that are minimally invasive, replacing venous blood draws from a phlebotomist with a simple fingerstick that anyone can perform. Aron is a serial entrepreneur, whose background combines a PhD from the University of Cambridge and a focus on microfluidics and biotechnology with strong experience in professional management. At Protein Logic, a spin-out from Cambridge University that raised more than £3 million in initial funding to develop proprietary biomarker technology for the diagnosis and prediction of diseases, he served as COO. At WiseMed, where he was Co-founder, his team developed crowdsourced medical diagnostic technology as an affordable solution for improving healthcare in the developing world. Now, at Orphidia, Aron is providing the vision and leadership that will usher in the next generation of medical diagnostics, empowering everyone to know their health.
Follow Aron Rachamim:
About Senzo: Senzo is a deep-tech bio-med company developing testing products and IP.
Melinda Nicci
Founder and CEO of Baby2Body
Melinda is founder and CEO of Body Collective (Baby2body) the award- winning, wellness company for women.
She is a Sports and Exercise Psychologist, author of two bestselling books, is a regular contributor on the BBC, and sits on numerous boards as a NED, including The ICE List and Team GB (Olympic and Para-olympics snow-sport teams).
Melinda was named the UKBAA High Growth Founder of the year 2019/20, and has won numerous accolades and awards for entrepreneurship, including being named in the UK list of the Most Influential Women in Tech for 4 years running.
A serial entrepreneur, she founded and sold her first business at the age of 25 in South Africa, and held the position of Senior Director for Consumer health Innovation at Philips in Amsterdam. Melinda brings her passion for sport, performance and wellness to the numerous companies she advises and has created a global business with Body Collective, helping millions of women all over the world to live healthier and happier lives.
Follow Melinda Nicci:
About Baby2Body, GB Snowsport, ICE List: Baby2Body is a fully automated health, fitness and wellbeing coaching platform for pregnant women and mothers.
Khoa Phan
CEO & Co-Founder of Backbone Labs, Inc.
Khoa’s entrepreneurial spirit and engineering experience drives the strategic vision of Backbone Labs, as well as the development of its products. Before he launched Backbone Labs, Khoa founded a successful marketing agency specializing in search, content and social media ad campaigns for acquiring customers and users. He has also co-founded an indie mobile game studio. When he’s not building companies, Khoa is an avid collector of rare sneakers.
Follow Khoa Phan:
About Backbone Labs, Inc.: Identify at-risk behavior in the workplace and recommend actions to promote and maintain overall back-related wellness.
Abdullah Sabyah
Founder and CEO of Rightangled
A scientist-entrepreneur and a healthcare professional, also a member of the British Heart Foundation Alliance, a member of the Clinical Pharmacogenomics Implementation Consortium in the US, and the inventor of a patent pending-technology for nucleic acid testing on a lateral flow assay (the patent is for a technology to detect DNA sequences in real-time).
Follow Abdullah Sabyah:
About Rightangled: Medtech specialised in Genetics, Blood and infection testing. Service is delivers through a platform that connects users with specialists.
Seyed-Mahdi Khaligh-Razavi
Co-Founder and Chief Science Officer of Cognetivity Neurosciences
Seyed-Mahdi Khaligh-Razavi is the Co-Founder and Chief Science Officer at Cognetivity Neurosciences.
Follow Seyed-Mahdi Khaligh-Razavi:
About Cognetivity Neurosciences: Cognetivity Neurosciences is a Platform technology for early, rapid and easy detection of dementia.
Andrea Spezzi
Chief Medical Officer & Co-Founder of Orchard Therapeutics
Andrea is a co-founder of Orchard Therapeutics and brings to the company extensive experience and expertise in the development and execution of all aspects of clinical development and particularly in paediatric rare diseases. Prior to joining Orchard Therapeutics, Andrea served as VP and Medicine Development Leader at GSK Rare Diseases Unit. Previous to joining the GSK Rare Diseases Unit, Andrea was Senior Medical Director at the Immune Inflammation Discovery Performance Unit. Before GSK, Andrea was Global Medical Director R&D at Takeda in the metabolic and cardiovascular area and in charge of the paediatric developments for Takeda Europe R&D. Before that, she worked as Research Physician at Hammersmith Medicines Research. Before moving to the pharmaceutical industry Andrea practiced as a paediatrician for 12 years in Argentina, Spain and UK. Andrea obtained her medical degree from the University of Buenos Aires (UBA) and completed residency in paediatrics and post graduate training in paediatric immunology at the Dr Elizalde Children’s Hospital in Buenos Aires, Argentina. She obtained a Specialist in Pharmaceutical Medicine degree from University of Basel, Switzerland and she is a Fellow of the Faculty of Pharmaceutical Medicine in London, UK (FFPM).
Follow Andrea Spezzi:
About Orchard Therapeutics: Orchard Therapeutics is a biotechnology company dedicated to transforming the lives of patients through innovative gene therapies.
Ali Parsa
Founder and CEO of Babylon
Ali is an entrepreneur and engineer. He built Circle to become Europe’s largest partnership of clinicians, achieving around £200M in annual revenue, 3000 employees and a successful IPO, all during an economic recession. He was named by The Times as among the 100 global people to watch, and was the recipient of the Royal Award for young entrepreneurs for founding V&G earlier in his career. Ali is a UK Cabinet Office Ambassador and has a PhD in engineering Physics.
Follow Ali Parsa:
About Babylon: Babylon is a world leading, digital-first, value-based care company.
Lana Ghanem
Founder & Managing Director of Hikma Ventures
Lana is managing director at Hikma Ventures which she helped establish in 2015. Lana started her career at Hikma Pharmaceuticals PLC in 2012 as the Assistant to the CEO and Director of Corporate Strategy & Development where she worked on strategic projects across the company’s various functions including strategy, M&A, operations and finance. Prior to joining Hikma, Lana worked as a Financial Analyst in the Mergers and Acquisitions department at Dresdner Kleinwort Investment Bank in London where she worked on transactions for clients across multiple industries. Lana holds an MBA from Harvard Business School (HBS) and a Bachelors of Commerce degree from McGill University.
Follow Lana Ghanem:
About Hikma Ventures: Hikma Ventures operates as the corporate venture capital arm of Hikma Pharmaceuticals.
Mathieu de Beaumont
Co-Founder / Director of Dementech
Co-Founder of Dementech Neurosciences
Follow Mathieu de Beaumont:
About : Neurology & Psychology experts
Michel Rabhi
Founder and Director of Dementech
Owner and Director at Dementech Neurosciences
Follow Michel Rabhi:
About : Neurology & Psychology experts
Pablo Graiver
President and Founder of Antidote.me
Pablo Graiver is Co-Founder of Antidote Technologies Ltd. (a/k/a TrialReach Ltd.) and serves as its Chief Executive Officer and Executive Director. Pablo Graiver served as Vice President of Business Development, Europe of Kayak Software Corporation. He has over 12 years of entrepreneurial and management experience in the online industry. He was an early member of NetJuice, one of the largest Internet incubators in Europe; MD at Donde Comprar.com, the first e-commerce directory in Spanish; and later co-founder and Vice President of Strategy at Kelkoo, acquired by Yahoo! in 2004. Pablo Graiver set up and launched Kayak.com in Europe, and served as European Sales Director at ValueClick (NASDAQ: VCLK). He studied Biology and Business Administration at UAM in Madrid.
Follow Pablo Graiver:
About Antidote.me: Antidote is a digital health company that accelerates and improves medical research by combining technologies, data, and business models.
Yeshwanth Pulijala
Founder & CEO of Scalpel
Follow Yeshwanth Pulijala:
About Scalpel: Scalpel provides a platform to optimize surgical procedures in clinics and hospitals.
Agnieszka Chomka
Co-Founder and Head of R&D of BioMe Oxford
Agnieszka is an intestinal immunologist at the Kennedy Institute for Rheumatology, University of Oxford. Her main research interests focus on the microbial-host interactions in the large intestine. She was awarded the prestigious Wellcome Trust scholarship at the University of Oxford to conduct her research into the role of a tissue-resident regulatory immune cell population in the gut. Agnieszka has published her results in top peer-review research journals.
Follow Agnieszka Chomka:
About BioMe Oxford, Globe Life Sciences: Unlocking your gut microbiome by developing a medical device for targeted and non-invasive sampling
Soren Krogsgaard Thomsen
Co-Founder, CEO and Managing Director of BioMe Oxford
Soren is a medical scientist at the University of Oxford, with a background in the natural sciences and genetics research. He previously worked as a consultant for pharma and OBR consulting, and has published on his experiences as an academic entrepreneur. Soren’s current research is focused on translating large-scale genetic data into mechanisms for disease to inform new therapeutic strategies. He dreams of one day enabling similar population-wide microbiome studies using the platform technology under development at BioMe Oxford Ltd.
Follow Soren Krogsgaard Thomsen:
About BioMe Oxford, Vertex Pharmaceuticals: Unlocking your gut microbiome by developing a medical device for targeted and non-invasive sampling
Patrick Albers
Co-Founder and Head of Technology of BioMe Oxford
Follow Patrick Albers:
About BioMe Oxford, Wellcome Trust Sanger Institute: Unlocking your gut microbiome by developing a medical device for targeted and non-invasive sampling
Fouad Al Noor
Co-Founder & CEO of ThinkSono
Fouad has a masters in Electronic Engineering with Nanotechnology from the University of Southampton. He worked as a research assistant at Imperial College London before joining Entrepreneur First. He wrote his thesis on paper-based medical diagnostics using image processing.
Follow Fouad Al Noor:
About ThinkSono: Cutting edge AI ultrasound software for detection of blood clots (DVT)
Sven Mischkewitz
CTO & Co-Founder of ThinkSono
Sven is an award-winning software engineer from Hasso-Plattner-Institute, Germany. Before joining Entrepreneur First, he worked on annotation tools for brain cells on projects for the Max-Planck-Institute for Brain Research. He focused on the field of Human-Computer-Interaction during his studies.
Follow Sven Mischkewitz:
About ThinkSono: Cutting edge AI ultrasound software for detection of blood clots (DVT)
Paul Cowan
Founder , Chairman & Chief Executive Officer of Quotient Biodiagnostics
Paul Cowan is our Chief Executive Officer and Chairman of our Board of Directors. Mr. Cowan founded us through the acquisition of Alba Bioscience in 2007. He has a broad range of healthcare industry experience gained through over 15 years of employment within industry and investment banking. Previously, Mr. Cowan served as the Chief Financial Officer of Inveresk Research Group, a global contract research organization that was acquired by Charles River Laboratories in 2004. Prior to joining Inveresk in 2001, Mr. Cowan was a senior executive within the Investment Banking department of Bear Stearns & Co., where he led the European biotechnology practice. Prior to Bear Stearns, Mr. Cowan was a senior executive within the Investment Banking department of Morgan Grenfell (acquired by Deutsche Bank in 1990). Mr. Cowan received a Bachelor of Business in accounting from Queensland University of Technology.
Follow Paul Cowan:
About Quotient Biodiagnostics: Quotient Biodiagnostics develops and manufactures products for use in transfusion diagnostics.
Shankar Balasubramian
Co-Founder and Director of Cambridge Epigenetix
Sir Shankar is Founder of two companies and the principal inventor of the leading next generation human genome sequencing technology core to all Illumina sequencing platforms, estimated to be worth >$30BN. Sir Shankar’s technology has made routine, accurate, low-cost sequencing of human genomes a reality, has revolutionised biology and accelerated the development of genomic personalised medicine. Sir Shankar is the Herchel Smith Professor of Medicinal Chemistry at the University of Cambridge and Senior Group Leader at the Cancer Research UK Cambridge Institute. His awards include the Royal Medal (2018), the RoyalSociety Mullard Award (2009), The BBSRC Innovator of the year (2010) and the Tetrahedron Prize (2013). He is a Fellow of the Royal Society, the Academy of Medical Sciences and a member of EMBO.
Follow Shankar Balasubramian:
About Ahren Innovation Capital, Cambridge Epigenetix: Cambridge Epigenetix is using epigenetics to reduce several routine & important diagnostic tests for common cancers to a simple blood draw.
Matt Elcock
Founder & CTO of Push Doctor
Follow Matt Elcock:
About Push Doctor: Push Doctor is creating the future of healthcare.
Eren Ozagir
Founder & Shareholder of Push Doctor
Follow Eren Ozagir:
About Push Doctor: Push Doctor is creating the future of healthcare.
Tariq Sethi
Co-Founder of Galecto
Professor Sethi is Head of Respiratory Medicine Kings Health Partners / Kings College London and was previously Professor of Respiratory and Lung Cancer Biology at the University of Edinburgh. He was educated at Cambridge and London Universities followed by junior hospital jobs in London. He gained a PhD at the Imperial Cancer Research Fund London and was subsequently appointed lecturer in Medicine at Edinburgh University. As an MRC Travelling Fellow, he worked at the Scripps Research Insitute California, returning to Edinburgh as a Wellcome Trust Senior Research Leave Fellow. His research interests are on the interaction between inflammation and lung cancer, focusing on the regulation of proliferation and apoptosis by growth factor and integrin mediated signalling. He is an author of numerous scientific papers and has edited books on lung cancer. Professor Sethi is also on the editorial board of THORAX.
Follow Tariq Sethi:
About AstraZeneca, Galecto, King’s College London: Galecto is a clinical stage biotechnology company focused on the development of novel treatments for fibrosis and cancer.
Clare Cooper
Founder and Vice President of Storm3
Clare Cooper is the Founder and Vice President at Storm3.
Follow Clare Cooper:
About Storm3: Storm3 are a global HealthTech talent marketplace, connecting organizations with the talent to drive their mission.
Ronan Cunningham
Founder and Chief Executive Officer of BrainWaveBank
Ronan has more than 20 years of experience in advanced engineering and product development. He was one of the founding members of ATA Engineering, an award-winning San Diego-based engineering company specializing in development of innovative hardware and software technologies for the aerospace and defence industries. His roles have included Director of Business Development and Director of New Technology Development. He is an Entrepreneur-in-Residence with the Northern Ireland Science Park. His expertise is in early stage technology development, innovation strategy, and technology commercialisation. He holds an MS in Aeronautics and Astronautics from MIT.
Follow Ronan Cunningham:
About BrainWaveBank, Cumulus Neuroscience: BrainWaveBank makes it possible to measure and track brain activity and cognitive performance for anyone, anytime, anywhere.
Himanshu Kataria
Founder, CEO and Managing Director of CLYZ Labs
Himanshu is an experienced NHS Academic Clinician with emergency medicine background (>10 years clinical experience). Himanshu has substantial experience in setup and delivery of clinical research trials, as a specialty lead within Clinical Research Network for the whole of North West Coast of England delivering research in >23 NHS Partner organisations. Himanshu is an MBBS, MBBS, MRCSed (A&E), MRCEM, FRCEM, ALS Instructor. With a number of years in both clinical and research experience, Himanshu has held various consultancy posts in notable hospitals/medical facilities such as Whiston Hospital in Merseyside. He also held the Special Group Lead position within the Clinical Research Network – North West Coast: Research Delivery arm of the NIHR (National Institute of Health Research). In addition to his qualifications as a Medical Doctor, Himanshu has held a number of entrepreneurial roles over the past few years in bio-medical companies such as Indu Stem Cell Technology Plc, and Transgenex Inc in the USA. Dr Kataria is familiar with financial management of the business owing to his experience in Clinical Finance Limited which advised for fundraising for Indu Stem Cell Technology PLC. He continues to serve as a director for Indu Stem Cell Technology PLC.
Follow Himanshu Kataria:
About CLYZ Labs: CLYZ Labs are developing a testing service to select the best drug therapy for personalised cancer treatment.
Lukas Lange
CEO and Co-Founder of Probably Genetic
Follow Lukas Lange:
About Probably Genetic: Probably Genetic helps rare genetic disease patients.
Pankaj Vadgama
Founder & Chief Scientific Officer of Camstech
Professor Pankaj Vadgama qualified in Medicine and Chemistry. He is Professor of Clinical Biochemistry and recently, Director of the Interdisciplinary Research Centre in Biomedical Materials, at Queen Mary University of London. His interests are in electrochemical biosensors for near-patient and in vivo monitoring, using miniaturised sensors and microdialysis. He has adapted biosensor chemistry for direct operation in biofluids and tissue, and has over 200 publications, 20 published patents. His underpinning research is in membrane technology for device packaging, and he was one of the first to report diffusion control membranes for extended linear range enzyme electrodes. He has variously worked on spider silk as an implant material, microfluidics for diagnostics, electrochemical characterisation of bone adhesives and is currently working on biodegradable sensors and on nanosilver as an antimicrobial for urine catheters. His has recently established a sensors spinout company, Camstech Ltd., to develop optical sensors
Follow Pankaj Vadgama:
About Camstech: Camstech develops novel sensing technology used for point-of-care diagnostics.
Jason Powell
Co-Founder of UK Vein Clinic
Follow Jason Powell:
About UK Vein Clinic: UK Vein Clinic is a group of venous surgeons and experts that specialize in treating varicose veins with endoscopic procedures.
Richard Wardle
Founder and Director of Vantix Diagnostics
Richard Wardle is the Founder of vantix® DIAGNOSTICS. Starting back in 1996 Richard led a team that identified and evaluated innovations from Russia. After identifying the biosensor opportunity he built a team around it to initiate the development process. Richard has been the driving force behind vantix® DIAGNOSTICS from its inception to the present time. Richard has been the Managing Director of a number of technology companies initially specializing in Eastern European technologies. Earlier in his career Richard was the Managing Director of a Construction/Engineering company specializing in contract construction of service stations on behalf of Shell U.K., major sports complexes and large scale residential developments while providing employment for up to 200 people. Prior to that he was the Managing Director of Aqua-Salve a dredging company specializing in ship recovery.
Follow Richard Wardle:
About Vantix Diagnostics: Vantix Diagnostics, Inc. operates Vantix, a biosensor platform for use in medical, veterinary, and environmental sectors. Its Vantix
Silja Litvin
Founder & CEO of PsycApps
I am a London based Psychologist, CEO and Founder of the Mental Health platform PsycApps. The mental health platform is also part of my PhD thesis in clinical psychology at the Ludwig Maximilian University (LMU) of Munich with help of Oxford University College. • In 2013 I finished my Masters in Psychology from LMU majoring in Family and Clinical Psychology. • As aforementioned I am currently completing my postgraduate education as a PhD student of the LMU with help of University College, Oxford. To help raise awareness for both mental well-being in general and our products, I speak at conferences and mental health panels. Being half German, half American, I speak fluent English and German. My French is decent and I understand Italian quite well. Because of my modelling career I am well-traveled, culturally diverse and I am by nature an extroverted people person. Media (1)This position has 1 media
Follow Silja Litvin:
About PsycApps, PsycApps, UCL, Wonder Women Tech: Digital Mental Health Games
Alberto Bardelli
Founder of Horizon Discovery
Alberto Bardelli is a professor at the University of Torino, He is also a Researcher and co-founder of Horizon Discovery, which is a successful British biotech company.
Follow Alberto Bardelli:
About Horizon Discovery: Horizon is a gene editing company that designs & engineers genetically-modified cells, applying them to advance human health.
Charalambos Antoniades
Founder and Chief Scientific Officer of Caristo Diagnostics
Follow Charalambos Antoniades:
About Caristo Diagnostics: Caristo Diagnostics utilises standard CT scans to identify potentially heart-stopping plaques
Neel Patel
Founder & Chief Executive Officer of ZiO Health
Follow Neel Patel:
About ZiO Health: ZiO Health has developed proprietary pocket-sized technology, bringing lab testing to the point of use.
Dr Vincent Forte
Founder of Forte Medical
Follow Dr Vincent Forte:
About Forte Medical: Forte Medical is a diagnostic center in London, England.
Stephen Dunniece
CTO & Founder of Cirdan
A founder of Cirdan, Stephen studied at Belfast Institute and the University of Ulster where he completed a MSc. in Electronics and Signal Processing. After working in the Physics Dept at QUB he joined Belfast start-up Andor Technology Ltd. For the next 7 years, he undertook all aspects of camera hardware design. In 1999, Stephen became Director of his own business, Audio Control Systems Ltd, involved in the design and installation of interactive equipment for the special needs sector.
Follow Stephen Dunniece:
About Cirdan: Cirdan delivers solutions that enable rapid implementation of a robust and scalable digital pathology workflow into a laboratory.
Cameron Shaw
Founder and COO of Virax Biolabs
Cameron Shaw is the founder and Chief Operations Officer at Virax Biolabs.
Follow Cameron Shaw:
About Virax Biolabs: Virax Biolabs is an innovative Biotechnology company focused on the prevention, detection and diagnosis of viral diseases
Jonathan Allis
Co-Founder & CEO of Blue Earth Diagnostics
Jonathan Allis is the founding CEO of Blue Earth Diagnostics. Prior to this role, Jonathan was the General Manager for PET at GE Healthcare Life Sciences, and had global responsibility for GE Healthcare’s PET agent and PET synthesis platforms business. He has previously held positions in R&D, Marketing and Product Development at GE Healthcare, Amersham plc., Siemens Medical Solutions and Oxford Magnet Technology, in the UK, USA and Germany. Jonathan has an undergraduate degree in Physics from the University of Cape Town and a doctorate in biochemistry from the University of Oxford.
Follow Jonathan Allis:
About Blue Earth Diagnostics: BlueEarth Diagnostics mission is to transform the clinical management of recurrent prostate cancer
Neciah Dorh
Co-Founder and CEO of FluoretiQ
Neciah Dorh is a Co-Founder and serves as the Chief Executive Officer at FluoretiQ.
Follow Neciah Dorh:
About FluoretiQ: FluoretiQ is a medical device company designing simple and effective bacterial detection systems for rapid diagnosis of infection.
Jon Holmes
Co-Founder and CEO of Michelson Diagnostics
Under Jon’s skilful and visionary leadership, Michelson Diagnostics Ltd has rapidly grown from a fledgling start-up in 2006, to the thriving company it is today. He has masterminded five rounds of investment, and his strategy for growth has enabled the company to achieve all of its milestones to date, on time and on budget.Jon was previously Business Director of the Biomedical Group at Sira, the instrumentation R&D company, and was Director of the Smart Optics Faraday Partnership.
Follow Jon Holmes:
About Michelson Diagnostics, Michelson Diagnostics, SmartOptics: Michelson Diagnostics develops and manufactures multi-beam Optical Coherence Tomography-based products.
David Lane
COO and Co-Founder of EProfiler Solutions
Follow David Lane:
About EProfiler Solutions: EProfiler Solutions develops technology solutions to diagnose diseases.
Billy Boyle
CEO and Co-Founder of Owlstone Nanotech
Since co-founding Owlstone, Billy has been overseeing the development and implementation of the detection technology with nanotechnology foundry partners. He is also active in business development, demonstrating to partners how the Owlstone technology can used to realise a paradigm shift in detection applications and deployment scenarios. Billy is heavily involved in the creation and realisation of new technologies and IP. Prior to joining Owlstone Billy was a Research Associate in the Microsystems and Nanotech group at Cambridge University. In an academic / industry consortium he designed and developed silicon-opto hybrid devices for next generation telecoms systems.
Follow Billy Boyle:
About Owlstone Nanotech: OWLSTONE is a platform technology, where regardless of the application, hardware remains the same & the app is enabled through software.
Adrian Hayday
Co-Founder of GammaDelta Therapeutics
Adrian Hayday was trained in biochemistry at Cambridge, and obtained a PhD in molecular virology from London University. He began studying immunology in 1982 at MIT, where he and his colleagues first described the wholly unanticipated T cell receptor gamma chain genes. Since then Professor Hayday has used many parameters to establish that gamma-delta T cells are clearly distinct from conventional T cells. Those parameters include the cells’ responses to different products of a novel gene family expressed at body surfaces, that Professor Hayday and his colleagues identified. He showed that this unique biology allows gamma-delta T cells to make rapid responses to tissue dysreguation, rather than to specific pathogens, and thereby to monitor tissue integrity. This may explain Professor Hayday’s observation that gamma-delta T cell deficiency is associated with a profound susceptibility to skin carcinogens, findings which were instrumental in promoting his and others’ interest in the cells’ clinical application. In other clinical activities, he directed a team describing the human immune response to vaccination and described the unique properties of human autoantibodies. Additionally, he is the lead-investigator of a Wellcome Trust-supported, multi-centre, high-throughput phenotyping screen identifying novel genetic regulators of the immune system. Professor Hayday has authored over 200 papers, of which he is first, last, or corresponding author on over 120, and of which 150 are original research contributions. He has received many awards, including the William Clyde deVaneMedal, Yale College’s highest honour for scholarship and teaching, an honorary fellowship of King’s College London, and the King’s College Business Award, 2008. He was elected to lead the British Society of Immunology (2005-09) and has organized many scientific meetings including the 2014 Gordon Conference in Immunochemistry and Immunobiology, and the scientific programme for the 2012 European Congress of Immunology. He is an elected fellow of the Academy of Medical Sciences and of the Royal Society. He has formally advised many institutions including Institut Pasteur; the Max Planck Institute; Kyoto University, the Wellcome Trust, and Cancer Research UK, whose science committee he chaired for three years. He has participated in many aspects of the biotech/pharmaceutical sector, including membership of the MedImmune SAB, and was a co-founder of ImmunoQure AG before co-founding GammaDelta Therapeutics in 2016.
Follow Adrian Hayday:
About GammaDelta Therapeutics: GammaDelta Therapeutics is developing the potential of gamma delta (γδ) cells
Matthew Hicks
Co-Founder & Chief Technology Officer of Linear Diagnostics
Matthew Hicks is a Founder and executive director of Linear Diagnostics Limited. He has 20 years experience in biochemistry and biophysics in academic and commercial sectors and has published over 40 research papers. Matt, who holds several patents, has a doctorate in Biophysics. He is a world-leader in linear dichroism spectroscopy which is the underlying technology of LDL.
Follow Matthew Hicks:
About Linear Diagnostics, University of Birmingham: Linear Diagnostics Limited is a diagnostics company based on a novel technology
Cath Booth
Founder and Director, Research Services of Epistem
Follow Cath Booth:
About Epistem, Epistem: Epistem’s specialist contract research services provide valuable support to drug discovery and development pipelines.
Sheraz Daya
Founder, Chairman & Medical Director of Centre for Sight
Follow Sheraz Daya:
About Centre for Sight: Centre for Sight provides eye care services, from basic diagnostic and therapeutic services to complex operative procedures.
Julie Barnes
Founder/ Chief Scientific Officer & Chief Executive Officer of Abcodia
Julie has over 20 years experience of the Pharmaceutical and Biotechnology industry, including 15 years experience of early R&D with GlaxoSmithKline. More recently Julie was director and Chief Scientific Officer at BioWisdom, a healthcare technology company. Her mix of scientific and commercial experience in large pharmaceutical and small start-ups and academic network brings a strong understanding of what is required to successfully lead Abcodia as an ethical and collaborative organisation.
Follow Julie Barnes:
About Abcodia: Abcodia is an innovative biotech company engaged in the validation and discovery of molecular biomarkers.
John Tidy
Medical Founder of Zilico
John Tidy is a Clinical Founder at Zilico.
Follow John Tidy:
About Zilico: Zilico is focused on developing next generation cancer diagnostics to provide real-time diagnosis for cervical cancer.